My sense is that CML is not behind this move. We need reported NRx to average near 60 to soundly beat the consensus.
Perhaps it is buyout mania, maybe some shorts cashing in, or perhaps setting up the next drop.
On dough's GIST post, the news for Tasigna being of no value add anywhere in GIST vs. Gleevec is amazing. Ponatinib possibly looking at 1st line, all line home run here.
On jaybe's ALK post, the competitors looking weaker by the moment. LDK cannot be tolerated at doses needed to even begin to combat brain mets. Chuggy won't even try. IMO, ESMO will predict with 90% confidence the winner/losers here.
TC has said the lung drugs show efficacy early, or not at all. They'll have the couple of months that is needed to show direction. Accordingly, we'll also either proceed the 790 trials or reportedly roll out the next 790 candidate, win-win.
Not a seller in sight. Low volume, but it feels a bit more solid than other days. Reality cautions we've had these $1-2days before.
